We thank Drs. Chatterton, Muzzio, and Gann for their comments regarding the methods that were used to determine estrogens in nipple aspirate fluid (NAF) and ductal lavage supernatant (DLS) [1] .
Dr. Chatterton et al. state ''Our concern is about their ability to measure any of the estrogens based on the method as described in the paper'' because ''only 0.0021 fmol'' was available. In fact, we injected, on average, 57.25 fg of unconjugated estradiol on-column for this study, an amount which is 5-6 times our assay limit of detection (LOD) [2] . We have included a figure  (Fig. 1) showing chromatograms from a typical NAF sample that was analyzed as part of this study. The peaks have excellent signal-to-noise ratios, demonstrating that the amount of dilute NAF injected on-column was well above the assay's LOD.
Dr. Chatterton et al. seem to have overlooked the facts that the NAF samples that were analyzed in the laboratory for estrogens had been previously collected using two different methods: (1) NAF in 0.5 mL normal saline collected in Nunc tubes; and (2) NAF collected in capillaries, which were small in size, making it very difficult to measure the exact volume of NAF. To carry out the estrogen analysis, we diluted all NAF samples to a final volume of 1 mL. This step is stated on page 521 of our manuscript: ''Prior to the sample preparation, NAF specimens collected with capillary tubes were first sonicated in acetone/ethyl alcohol (1:1 v/v) for 30 min to quantitatively recover estrogens and estrogen metabolites from the glass capillaries followed by lyophilization to dryness, and were then reconstituted in 100 lL ethanol and 900 lL of 0.15 M sodium acetate buffer (pH 4.6) [1] .'' Estrogen analysis was subsequently conducted on the 1 mL of diluted NAF. In Table 3 of our manuscript, the NAF estrogen concentrations in 1 mL of diluted NAF are expressed as pmol/L. In fact, if our original NAF (before diluting to 1 mL) was truly 10 lL in volume, the unconjugated estradiol geometric mean concentration would be 114.5 pg/mL, which is similar to the levels reported by Dr. Chatterton et al. [3] . Dr. Chatterton et al. were confused by our statement ''For purposes of this study, all BRCA1 or BRCA2 mutation positive postmenopausal women with sufficient volumes of serum, NAF and/or DLS specimens (C0.5 mL) were eligible for inclusion.'' We apologize for the imprecision in our language. We intended the ''C0.5 mL'' to apply only to the DLS specimens.
Dr. Chatterton et al. also point out the difficulty of estimating concentrations from DLS. We agree with this point, as mentioned in the Discussion of the paper.
